BR9812316A - Formulações de camptotecina lipossÈmica - Google Patents

Formulações de camptotecina lipossÈmica

Info

Publication number
BR9812316A
BR9812316A BR9812316-5A BR9812316A BR9812316A BR 9812316 A BR9812316 A BR 9812316A BR 9812316 A BR9812316 A BR 9812316A BR 9812316 A BR9812316 A BR 9812316A
Authority
BR
Brazil
Prior art keywords
formulations
camptothecin
liposomes
liposomal camptothecin
liposomal
Prior art date
Application number
BR9812316-5A
Other languages
English (en)
Inventor
Karen Lewis Moynihan
David Lloyd Emerson
Su-Ming Chiang
Ning Hu
Original Assignee
Nexstar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexstar Pharmaceuticals Inc filed Critical Nexstar Pharmaceuticals Inc
Publication of BR9812316A publication Critical patent/BR9812316A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"FORMULAçõES DE CAMPTOTECINA LIPOSSÈMICA"<D>. São providas formulações de camptotecina encapsuladas em lipossomos. Os lipossomos possuem farmacocinética aperfeiçoada, eficácia melhorada como agentes antitumor e fornecem índice terapêutico aumentado, quando comparados ao medicamento livre e topotecan. As formulações incluem lipossomos compreendendo pelo menos um fosfolipídeo e uma camptotecina ou análogo a mesma.
BR9812316-5A 1997-09-16 1998-09-15 Formulações de camptotecina lipossÈmica BR9812316A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5908397P 1997-09-16 1997-09-16
PCT/US1998/019086 WO1999013816A2 (en) 1997-09-16 1998-09-15 Liposomal camptothecin formulations

Publications (1)

Publication Number Publication Date
BR9812316A true BR9812316A (pt) 2001-03-20

Family

ID=22020747

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812316-5A BR9812316A (pt) 1997-09-16 1998-09-15 Formulações de camptotecina lipossÈmica

Country Status (8)

Country Link
EP (1) EP1037610A4 (pt)
JP (1) JP2003510239A (pt)
KR (1) KR100711315B1 (pt)
AU (1) AU751439B2 (pt)
BR (1) BR9812316A (pt)
CA (1) CA2303366A1 (pt)
NZ (1) NZ503293A (pt)
WO (1) WO1999013816A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1121102T3 (da) 1998-09-16 2003-08-11 Alza Corp Liposomindesluttede topoisomeraseinhibitorer
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
DE60115045T2 (de) * 2000-06-30 2006-08-03 Inex Pharmaceuticals Corp., Burnaby Verbesserte liposomale camptothecine und deren verwendungen
US7452550B2 (en) 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
IL155696A0 (en) * 2000-11-09 2003-11-23 Neopharm Inc Sn-38 lipid complexes and methods of use
DE10157994A1 (de) * 2001-05-25 2003-01-02 G O T Therapeutics Gmbh Liposomal verkapselte hydrophobe Wirkstoffe mit hohem Wirkstoffgehalt >50% sowie Verfahren zur Herstellung pharmazeutischer Zubereitungen, die liposomal verkapselte hydrophobe Wirkstoffe umfassen
AU2003249882B2 (en) * 2002-06-26 2008-09-18 Medigene Ag Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
EP1393719A1 (en) * 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
CA2506749A1 (en) * 2002-11-26 2004-06-10 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
AU2005304914B2 (en) * 2004-11-05 2012-02-16 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
WO2008070009A2 (en) * 2006-12-01 2008-06-12 Alza Corporation Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
TWI428135B (zh) 2007-03-26 2014-03-01 Hirofumi Takeuchi And a carrier composition for quick-acting nucleic acid delivery
KR101130754B1 (ko) 2010-06-25 2012-03-28 제일약품주식회사 난용성 트리사이클릭 유도체 화합물의 용해도가 향상된 약학적 조성물
AU2013203682B2 (en) * 2011-08-25 2016-03-31 Trophos Liposome comprising at least one cholesterol derivative
FR2979239A1 (fr) * 2011-08-25 2013-03-01 Trophos Liposome comprenant au moins un derive de cholesterol
WO2014047116A1 (en) * 2012-09-18 2014-03-27 Comfort Care For Animals Llc Encapsulating liposomes
MX2015005992A (es) 2012-11-20 2016-03-07 Spectrum Pharmaceuticals Inc Metodo mejorado para la preparacion de la vincristina liposomal encapsulada para el uso terapeutico.
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
KR102162351B1 (ko) 2018-11-08 2020-10-06 순천향대학교 산학협력단 약물-결합 화합물 및 이의 용도
CN115721610A (zh) * 2021-08-27 2023-03-03 沈阳药科大学 一种7-乙基-10-羟基喜树碱复方脂质体及其制备方法和应用
CN116327701A (zh) * 2023-02-27 2023-06-27 北京大学深圳医院（北京大学深圳临床医学院） 用于治疗肝纤维化的复合纳米脂质体及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5554382A (en) * 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes
EP0721328A4 (en) * 1993-09-27 1997-09-17 Smithkline Beecham Corp CAMPTOTHECIN FORMULATIONS

Also Published As

Publication number Publication date
KR100711315B1 (ko) 2007-04-27
EP1037610A1 (en) 2000-09-27
NZ503293A (en) 2002-09-27
WO1999013816A2 (en) 1999-03-25
EP1037610A4 (en) 2004-07-07
AU751439B2 (en) 2002-08-15
AU9387798A (en) 1999-04-05
WO1999013816A3 (en) 2001-11-01
CA2303366A1 (en) 1999-03-25
JP2003510239A (ja) 2003-03-18
KR20010030599A (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
BR9812316A (pt) Formulações de camptotecina lipossÈmica
HK1245320A1 (zh) 治療缺陷α半乳糖苷酶A的藥物製劑
ATE192657T1 (de) Arzneistoffzusammensetzung, die ein nukleinsäurecopolymer enthält
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
DE69627690D1 (de) Liposomale formulierungen von mitoxantron
ES2130428T3 (es) Cristales de insulina asp-b28.
AU2874099A (en) Low molecular weight compounds administered together with anti-cancer agents to treat cancer and pharmaceutical compositions thereof
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
WO2002083097A3 (en) Drug delivery system for hydrophobic drugs
CA2284732A1 (en) Analogs of cocaine
WO2001066123A3 (en) Composition consisting of phy906 and chemotherapeutic agents
WO2001087227A3 (en) Drug containing polymeric micelles
AU2800689A (en) Differential delivery of therapeutic agents across the blood brain barrier
BR0111541A (pt) Formulações lipossÈmicas inibidoras de timidilato sintase de benzoquinazolina
WO1999002143A3 (en) Medicament comprising adenosine
TR199903192T2 (xx) Eritropoetin, de�i�tirilmi� hemoglobin i�eren farmasotik kombine m�stahzarlar.
ATE272648T1 (de) Glycokonjugate von 20(s)-camptothecin
RS11104A (en) Combined preparations,containing 1,4- benzothiepine-1,1- dioxide derivatives and other active substances, and the use thereof
AU5326598A (en) New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them
BR9812160A (pt) Derivados de benzoxazina e benzotiazina e seu emprego em medicamentos
IL115652A (en) Use of vWF or fragments thereof for the preparation of medicaments having an antidote effect to antithrombotic and/or fibrinolytic agents producing hemorrhages
AU8553898A (en) Use of 2,3-benzodiazepine derivatives for the preparation of pharmaceutical compositions to treat diseases connected with the endogenous opioid system
WO1998036778A8 (en) Sustained drug delivery and compositions useful therefor
WO1999021538A3 (de) Verwendung von glykosaminoglykanen zur herstellung von pharmazeutischen zubereitungen zur behandlung von mit diabetes assoziierten augenkrankheiten

Legal Events

Date Code Title Description
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO COM BASE NOS ARTIGOS 8O E 13 DA LPI